Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DBI UC-MSC in Frailty Patients
NCT07449364Completed
- Sponsor
- Daewoong Group Indonesia
- Start
- Mar 2025
- Primary completion
- Dec 2025
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Open-label, single-arm trial of UC-MSC injection (Shandong Province Qilu Stem Cells Engineering) in frailty syndrome, sponsored by Daewoong Group Indonesia. Primary endpoints: Safety evaluation (Adverse Events) at 6 months, Safety evaluation (Acute reactions) at 6 months and 4 more. Started Mar 2025; status: completed.
02
Drugs
UC-MSC injection (Shandong Province Qilu Stem Cells Engineering)
03
Conditions
frailty syndrome
Beyond the preview
Go deeper on NCT07449364.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07449364.